Abstracts tagged "spondyloarthritis"

Abstract Number: 1434 • ACR Convergence 2025
Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Adam Mayer¹, Rui Xiao², Meenakshi Bewtra³, Michael George⁴ and Pamela Weiss⁵, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The potential that nonsteroidal anti-inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing joint pain in…
Abstract Number: 0591 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Felipe Julio Ramirez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Jérémy Lambert¹², Rajan Bajracharya¹³, Patrik Öhagen¹⁴ and William Tillett¹⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Colombes, France, ¹³UCB, Slough, England, United Kingdom, ¹⁴UCB, Stockholm, Sweden, ¹⁵Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody…
Abstract Number: 0545 • ACR Convergence 2025
Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
Omar-Javier Calixto¹, Uta Kiltz², Brikena Lalazi³, Franziska Neinert³, Philipp Sewerin⁴ and Xenofon Baraliakos², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque, Herne, Nordrhein-Westfalen, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany
Background/Purpose: The phenotypes of axial spondyloarthritis (axSpA) and clinical responses to placebo and study drugs in randomized controlled trials (RCTs) have changed over time. We…
Abstract Number: 0412 • ACR Convergence 2025
The Association of Obesity with Juvenile Spondyloarthritis
Katelyn Baggett¹, Timothy Brandon² and Pamela Weiss³, ¹Johns Hopkins University, Newtown Square, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Childhood obesity is a global public health concern that impacts the health and wellbeing of all children and particularly negatively affects children living with…
Abstract Number: 2355 • ACR Convergence 2025
Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
KURT OELKE¹, Sarah Ross², Emily Edson-Heredia³, Jennifer Pustizzi⁴, Ali Sheikhi Mehrabadi⁵, Natalia Bello⁵, Frederick Murphy⁶, Shikha Singla⁷, Siba Raychaudhuri⁸, Philip J Mease⁹ and Arthur Kavanaugh¹⁰, ¹rheumatic disease center, Glendale, WI, ²Lilly, Indianapolis, IN, ³eli lilly, indianapolis, ⁴Eli Lilly, Hammonton, NJ, ⁵Eli Lilly, Indianapolis, IN, ⁶Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁷Medical College of Wisconsin, Milwaukee, WI, ⁸UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁹University of Washington, Seattle, WA, ¹⁰University of California, San Diego, School of Medicine, San Diego, CA

Background/Purpose: Ixekizumab (IXE) is an FDA-approved monoclonal antibody that targets interleukin-17A.Methods: Psoriatic Arthritis Real-World Study in the US (PARTUS) was a prospective, multicenter, non-interventional cohort…
Abstract Number: 2318 • ACR Convergence 2025
Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
Khalid Alnaqbi¹, Mohammed Alaswad², Tariq Al Araimi³, Amr Mahmoud⁴, Samar Al emadi⁵, Hanan Al Rayyes⁶, Khuloud Mohammed⁷ and Xenofon Barliakos⁸, ¹Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, ²Faculty of Human Medicine, University of Hama, Hama, Syria, ³Royal Hospital, Muscat, Oman, ⁴Department of Pharmacology, Pharmacy Program, Oman College of Health Sciences, Muscat, Oman, ⁵Hamad medical corporation, Doha, Qatar, ⁶Department of Medicine, Prince Sultan Military Medical City, Riyad, Saudi Arabia, ⁷Farwaniya Hospital, Kuwait, Kuwait, ⁸Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: There is a dearth of literature exploring challenges faced by rheumatologists in the referral, diagnosis, management, and monitoring of patients with suspected axial spondyloarthritis…
Abstract Number: 1755 • ACR Convergence 2025
Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
Zoya Qaiyum¹, Michael Tang², Shirin Soleimani³, Addison Pacheco², Melissa Lim⁴, Fataneh Tavasolian⁴, Trevor Pugh³ and Robert Inman², ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. We…
Abstract Number: 1432 • ACR Convergence 2025
Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
Tae-Hwan Kim¹, Bora Nam², Jung Ho Yang³, So-Young Bang⁴, Ji Hui Shin⁵, Seunghun Lee⁶ and Tae-jong Kim⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Preventive Medicine, Graduate School of Chonnam National University, Gwangju, Republic of Korea, ⁴Hanyang University, Seoul, Republic of Korea, ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁶College of Medicine, Hanyang University, Seoul, Republic of Korea, ⁷Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea
Background/Purpose: This study evaluates the impact of the ASAS definition of early axial spondyloarthritis (axSpA) on radiographic progression over a 12-year period, utilizing the Modified…
Abstract Number: 0589 • ACR Convergence 2025
Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials
Sofia Ramiro¹, Anna Molto², Elena Nikiphorou³, Marcelo Pinheiro⁴, Jamie Urbanik⁵, Tianming Gao⁶, Shirley Chen⁷, Jayne Stigler⁸, Jessica A. Walsh⁹ and Lihi Eder¹⁰, ¹Leiden University Medical Center, Bunde, Netherlands, ²Assistance Publique Hôpitauxde Paris, Paris, France, ³King's College London, London, United Kingdom, ⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ⁵AbbVie, Grayslake, IL, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Somerset, NJ, ⁸AbbVie, Round Lake, IL, ⁹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: Evidence suggests that the treatment effectiveness of TNFis and IL-17is is higher in male (M) vs female (F) patients (pts) with axSpA.1,2 Data comparing…
Abstract Number: 0543 • ACR Convergence 2025
Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
Nora Vladimirova¹, Anna EF Hadsbjerg², Simon Krabbe³, Adrian Ciurea⁴, Kristýna Bubová⁵, Monika Gregova⁵, Michael Nissen⁶, Burkhard Moeller⁷, Raphael Micheroli⁴, Susanne Pedersen⁸, Jakub Zavada⁵, Ziga Snoj⁹, Karlo Pintaric⁹, Bjorn Gudbjornsson¹⁰, Ziga Rotar¹¹, iris Eshed¹², Iwona Iwona Sudol-Szopinska¹³, Kasper Gosvig¹⁴, Torsten Diekhoff¹⁵, Robert G. W. Lambert¹⁶, Manouk de Hooge¹⁷, Maurice Donzallaz¹⁸, Alexander Bernatschek¹⁸, Merete Hetland¹⁹, Lykke Ørnbjerg²⁰ and Mikkel Ostergaard²¹, ¹Rigshospitalet-Glostrup, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, COPECARE, Glostrup, Denmark, ³Rigshospitalet, København, Denmark, ⁴University Hospital Zurich, Zurich, Switzerland, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁶Rheumatology Department, Geneva University Hospital, Geneva, Switzerland, ⁷Department of Rheumatology and Immunology, Inselspital, University Hospital Bern,, Bern, Swaziland, ⁸Rigshospitalet, København �, Denmark, ⁹Institute of Radiology, UMC Ljubljana,, Ljubliana, Slovenia, ¹⁰Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹University Medical Centre Ljubljana, Ziri, Slovenia, ¹²Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹³Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ¹⁴Department of Radiology, Copenhagen University Hospital Herlev-Gentofte,, Copenhagen, Denmark, ¹⁵Charite Universitetsmedizin Berlin, Berlin, Germany, ¹⁶University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ¹⁷Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ¹⁸Department of Rheumatology, University Hospital of Zurich, University of Zurich,, Zurich, Switzerland, ¹⁹Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ²⁰Rigshospitalet, Glostrup, Denmark, ²¹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Axial involvement in psoriatic arthritis (axPsA) is associated with more severe disease and greater pain compared to PsA with only peripheral disease. However, a…
Abstract Number: 0405 • ACR Convergence 2025
Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study
Hermine Brunner¹, Ivan Foeldvari², Gerd Horneff³, Antonio Mera Varela⁴, Angelo Ravelli⁵, Sharonjeet Kaur⁶, Swapnil Suhas Dahale⁷, Ruvie Martin⁸, Daniel Lovell¹, Alberto Martini⁹ and Nicolino Ruperto¹⁰, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³Asklepios Klinik, Hamburg, Germany, ⁴Rheumatology Division. Hospital Clínico Universitario de Santiago and Instituto de Investigaciones Sanitarias (IDIS), School of Medicine, Santiago de Compostela, Spain, ⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷IQVIA, Mumbai, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Università di Genova, Genova, Italy, ¹⁰Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy
Background/Purpose: Secukinumab demonstrated efficacy and safety in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), for up to…
Abstract Number: 2354 • ACR Convergence 2025
ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
José Miguel Sequí-Sabater¹, Pablo Beltrán Martin-Lorente², Sonia Pastor Navarro³, Maria del Carmen Lopez Gonzalez⁴, Maria Sanchez-Wonenburger⁵, DESAMPARADOS CASADO POVEDA³ and Anna Martínez Cristóbal⁶, ¹La Ribera University Hospital, Rheumatology Department, Gandía, Spain, ²Universidad Católica de Valencia "San Vicente Mártir", Valencia, Comunidad Valenciana, Spain, ³La Ribera University Hospital, Rheumatology Department, Valencia, Comunidad Valenciana, Spain, ⁴La Ribera University Hospital, Rheumatology Department, Cullera, Comunidad Valenciana, Spain, ⁵Hospital Universitario de La Ribera, València, Comunidad Valenciana, Spain, ⁶La Ribera University Hospital, Rheumatology Department, Alzira, Comunidad Valenciana, Spain

Background/Purpose: While traditional analysis relies on statistical software such as SPSS, emerging tools like ChatGPT introduce the possibility of performing statistical tests, interpreting results, and…
Abstract Number: 2316 • ACR Convergence 2025
Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores
Gabriela Moreira¹, Hemerli De Cinque Almeida Esteves², Nicole Felix³ and Jose Fernando Verztman¹, ¹Hospital Federal dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, ²No current affiliation, Columbus, OH, ³Federal University of Campina Grande, Fortaleza, Ceara, Brazil
Background/Purpose: Beyond musculoskeletal manifestations, there is growing recognition of the systemic and psychosocial burden of axial spondyloarthritis (axSpA). Sexual health is an often-overlooked aspect of…
Abstract Number: 1754 • ACR Convergence 2025
B3GNT2 Regulates Integrin β3 Glycosylation and Th17/Treg Imbalance in Axial Spondyloarthritis Pathogenesis
Chengchun Geng¹, Dachun Zhuo¹, Jiucun Wang² and Jing Liu¹, ¹Fudan University, Shanghai, Shanghai, China (People's Republic), ²Fudan University, Shanghai, China (People's Republic)
Background/Purpose: The rs6759298 variant near B3GNT2 is associated with Axial Spondyloarthritis (AS); however, its pathogenic mechanisms remain unknown. In this study, we explored the role…
Abstract Number: 1430 • ACR Convergence 2025
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Stylianos Georgiadis¹, Lykke Ørnbjerg¹, Brigitte Michelsen², Tore K. Kvien², Mehrdad Shoae Kazemi¹, Bente Glintborg¹, Anne Gitte Loft³, Rita Fonseca⁴, Helena Santos⁵, Andreas Reich⁶, Anne C. Regierer⁶, Jarno Rutanen⁷, Laura Kuusalo⁸, Gary Macfarlane⁹, Gareth T. Jones⁹, Adrian Ciurea¹⁰, Michael J. Nissen¹¹, Bjorn Gudbjornsson¹², Olafur Palsson¹³, Ziga Rotar¹⁴, Katja Perdan Pirkmajer¹⁵, Daniela Di Giuseppe¹⁶, Merete Hetland¹⁷ and Mikkel Ostergaard¹⁸, ¹Rigshospitalet, Glostrup, Denmark, ²Diakonhjemmet Hospital, Oslo, Norway, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Unidade Local de Saúde de Entre Douro e Vouga, Santa Maria da Feira, Portugal, ⁵Instituto Português de Reumatologia, Lisbon, Portugal, ⁶German Rheumatology Research Center, Berlin, Germany, ⁷Tampere University Hospital, Tampere, Finland, ⁸Turku University Hospital, Turku, Finland, ⁹University of Aberdeen, Aberdeen, United Kingdom, ¹⁰University Hospital Zurich, Zurich, Switzerland, ¹¹Geneva University Hospital, Geneva, Switzerland, ¹²Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³University of Iceland, Reykjavik, Iceland, ¹⁴University Medical Centre Ljubljana, Ziri, Slovenia, ¹⁵University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁶Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, ¹⁷Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ¹⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…

« Previous Page
1
…
4
5
6
7
8
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].